Harmony Biosciences Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

• Harmony Biosciences Holdings Inc HRMY.OQ reported quarterly adjusted earnings of 68 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 20 cents. The mean expectation of eleven analysts for the quarter was for earnings of 75 cents per share. Wall Street expected results to range from 39 cents to $1.00 per share.

• Revenue rose 16% to $200.49 million from a year ago; analysts expected $203.60 million.

• Harmony Biosciences Holdings Inc's reported EPS for the quarter was 68 cents​.

• The company reported quarterly net income of $39.78 million.

• Harmony Biosciences Holdings Inc shares had risen by 10.6% this quarter and gained 1.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.3% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Harmony Biosciences Holdings Inc is $48.00, about 27.2% above its last closing price of $34.94

This summary was machine generated from LSEG data August 6 at 05:07 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)